読み込み中
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
前日終値
$1.13
+$0.02 · +1.80%
日中の時刻はETです。市場データは遅延する場合があります。
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
日中レンジ
現在 $1.13
52週レンジ
現在 $1.13
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
74
割安
センチメント
55
まちまち
リスク
65
高リスク
モメンタム
32
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
日中レンジ
現在 $1.13
52週レンジ
現在 $1.13
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（AUD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 270.74万 AUD | 363.34万 AUD | 29.92万 AUD | 29.24万 AUD | 8831 AUD |
| 売上原価 | 481.03万 AUD | 359.41万 AUD | — | — | — |
| 粗利益 | −210.29万 AUD | 3.93万 AUD | 29.92万 AUD | 29.24万 AUD | 8831 AUD |
| 研究開発 | — | 2751.52万 AUD | 1755.94万 AUD | 1380.04万 AUD | 412.48万 AUD |
| 販売・一般管理 | 1586.14万 AUD | 1652.6万 AUD | 1521.82万 AUD | 1302.1万 AUD | 1084.79万 AUD |
| 営業費用 | 6473.25万 AUD | 3821.31万 AUD | 3692.01万 AUD | 3480.04万 AUD | 1992.52万 AUD |
| 受取利息 | — | 88.82万 AUD | 5.05万 AUD | 14.5万 AUD | — |
| 支払利息 | 10.99万 AUD | 6.53万 AUD | 64.29万 AUD | 8.61万 AUD | 934.97万 AUD |
| 減価償却費と償却費 | 274.7万 AUD | 270.16万 AUD | 300.26万 AUD | 324.58万 AUD | 298.29万 AUD |
| 営業利益 | −6683.54万 AUD | −3817.39万 AUD | −3662.09万 AUD | −3450.81万 AUD | −1991.64万 AUD |
| 純利益 | −5394.41万 AUD | −3834.25万 AUD | −4794.91万 AUD | −3461.12万 AUD | −3033.9万 AUD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$6.00
上昇余地（430.97%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
